AMGEN INC (AMGN)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$12,038.0M
Cash & Equivalents
$2,189.0M
Quarterly Burn Rate
$181,374M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (15 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
RITUXIMAB-ARRX
RIABNI |
APPROVED | Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Adenocarcinoma of the Gastroesophageal Junction, Advanced Malignancy, Advanced Solid Tumors, Anemia, Arthritis, Psoriatic, Asthma, Atopic Dermatitis, Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Breast Cancer, Cancer, Caregivers, Celiac Disease, Chemotherapy-Induced Thrombocytopenia, Chronic Kidney Disease, Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Myelomonocytic Leukemia, Chronic Obstructive Pulmonary Disease (COPD), Chronic Rhinosinusitis With Nasal Polyps, Circulating Tumor Cells, Cirrhosis, Colo-rectal Cancer, Colorectal Cancer, Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma, Coronary Artery Disease, Crohn's Disease, Cutaneous Lupus, Cutaneous Melanoma, Diabetes Mellitus, Diabetic Nephropathy, Discoid Lupus, Drug Toxicity, Electrocardiography, Erosive Osteoarthritis, Esophageal Cancer, Extensive-Stage Small-Cell Lung C |
|
EVOLOCUMAB
REPATHA |
APPROVED | — |
|
USTEKINUMAB-AUUB
WEZLANA |
APPROVED | — |
|
AFLIBERCEPT-AYYH
PAVBLU |
APPROVED | — |
|
ECULIZUMAB-AEEB
BKEMV |
APPROVED | — |
|
TARLATAMAB-DLLE
IMDELLTRA |
APPROVED | — |
|
ADALIMUMAB-ATTO
AMJEVITA |
APPROVED | — |
|
BEVACIZUMAB-AWWB
MVASI |
APPROVED | — |
|
ROMOSOZUMAB-AQQG
EVENITY |
APPROVED | — |
|
SOTORASIB
LUMAKRAS |
APPROVED | — |
|
TRASTUZUMAB-ANNS
KANJINTI |
APPROVED | — |
|
ERENUMAB-AOOE
AIMOVIG |
APPROVED | — |
|
INFLIXIMAB-AXXQ
AVSOLA |
APPROVED | — |
|
IVABRADINE HYDROCHLORIDE
CORLANOR |
NDA | — |
|
IVABRADINE
CORLANOR |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.